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Abstract
Oxidative stress plays an important role in the progression of various neuronal diseases including ischemia. Heat
shock protein 22 (HSP22) is known to protect cells against oxidative stress. However, the protective effects and
mechanisms of HSP22 in hippocampal neuronal cells under oxidative stress remain unknown. In this study, we
determined whether HSP22 protects against hydrogen peroxide (H2O2)-induced oxidative stress in HT-22 using
Tat-HSP22 fusion protein. We found that Tat-HSP22 transduced into HT-22 cells and that H2O2-induced cell death,
oxidative stress, and DNA damage were significantly reduced by Tat-HSP22. In addition, Tat-HSP22 markedly
inhibited H2O2-induced mitochondrial membrane potential, cytochrome c release, cleaved caspase-3, and Bax
expression levels, while Bcl-2 expression levels were increased in HT-22 cells. Further, we showed that Tat-HSP22
transduced into animal brain and inhibited cleaved-caspase-3 expression levels as well as significantly inhibited
hippocampal neuronal cell death in the CA1 region of animals in the ischemic animal model. In the present study,
we demonstrated that transduced Tat-HSP22 attenuates oxidative stress-induced hippocampal neuronal cell death
through the mitochondrial signaling pathway and plays a crucial role in inhibiting neuronal cell death, suggesting
that Tat-HSP22 protein may be used to prevent oxidative stress-related brain diseases including ischemia.
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Introduction
Heat shock proteins (HSPs) are known to be stress-
inducible proteins and are found in all organism. They
play an important role in cell survival in cells exposed to
biological stresses such as oxidative stress or chemical
stress [1–3]. The HSP family are classified based on their
molecular weight including HSP70, HSP90, HSP110.
Small HSPs are highly conserved and well characterized
as playing the role of molecular chaperones, and having
a protective function against biological stress [4–7].
Among HSPs, HSP22 is known as a member of the
family of small HSPs containing α-crystal domains,
preferentially expressed in heart, and having protective
effects against various conditions such as oxidative
stress, aging, cancer, and apoptosis [8–11]. Other studies
have demonstrated overexpression of HSP22 promotes
cardioprotection in an ischemic preconditioning animal
model by inhibition of iNOS production and mitochon-
drial dysfunction [12, 13].
The mitochondria play an important role in multiple
cellular processes including apoptosis [14]. Mitochondria
are known as one of the major sources of reactive
oxygen species (ROS) production as a by-product of
cellular processes. Excessive ROS causes damage to
macromolecules, subsequently leading to mitochondria
dysfunction and cell death [14–16]. Other studies have
showed that mitochondrial dysfunction is associated
with ROS production and mitochondria as well as with
ischemic damage [12–16]. However, the exact biological
function and precise mechanism of HSP22 protein in
ischemic neuronal damage remains poorly understood.
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Protein transduction domains (PTDs) facilitate the
delivery of molecules including proteins into cells or
tissues. Thus, PTDs were widely used as a tool to inves-
tigate the effect of target proteins in a number of
diseases [17–20]. Many studies have demonstrated that
PTD fusion protein transduced in vitro and in vivo and
markedly inhibited stress induced cell death [21–26].
In this study, we cloned, expressed, and purified the
Tat-HSP22 protein to examine the effect of Tat-HSP22
in ischemic neuronal damage. Our data demonstrate
that Tat-HSP22 protein significantly inhibits oxidative
stress-induced hippocampal HT-22 cell death and mito-
chondrial dysfunction, suggesting Tat-HSP22 protein
may allow for the development of a therapeutic protein
for neuronal diseases including ischemia.
Results
Identification of cell permeable Tat-HSP22 protein
The full length human HSP22 gene was obtained from a
liver cDNA library using PCR. The produced gene was
digested with restriction enzymes (Xho I and Bam HI)
and the gene was cloned into a Tat expression vector to
produce cell permeable Tat-HSP22 protein. As shown in
Fig. 1a, the resulting Tat-HSP22 protein expression vec-
tor contained histidine residue and Tat peptide whereas
a HSP22 expression vector was constructed as a control
without the Tat peptide. The constructed Tat-HSP22 and
control HSP22 protein expression vectors were con-
firmed by digestion with the same restriction enzymes
(Xho I and Bam HI) and DNA sequencing analysis (data
not shown).
To purify the Tat-HSP22 and control HSP22 protein,
the proteins were induced by adding 0.5 mM IPTG and
cultured at 37 °C for 4 h. After expression of Tat-HSP22
and control HSP22 proteins, these proteins were purified
using Ni-NTA affinity chromatography. Subsequently,
we performed PD-10 column chromatography to re-
moved salt from the purified proteins. SDS-PAGE and
Western blot analysis using an anti-histidine antibody
showed that purified Tat-HSP22 and control HSP22
protein bands correspond with the expected molecular
weight of HSP22 protein (Fig. 1b and c).
Transduction ability of Tat-HSP22 protein into HT-22 cells
To determine whether Tat-HSP22 proteins transduced
into hippocampal HT-22 neuronal cells, HT-22 was
treated with Tat-HSP22 or control HSP22 proteins
(0.5-5 μM) for 2 h or with Tat-HSP22 or control
HSP22 proteins (5 μM) over various time periods
(10–120 min). The levels of transduced Tat-HSP22 pro-
tein were measured by Western blotting using an anti-
histidine antibody. Westering blot analysis indicated that
Fig. 1 Construction and purification of Tat-HSP22 protein. a Diagram of expressed Tat-HSP22 and control HSP22 proteins. Tat-HSP22 expression
vector was constructed using pET15b vector. Purification of Tat-HSP22 and control HSP22 protein. After proteins were expressed by IPTG, the
proteins were purified using Ni-NTA affinity chromatography. Then, purified proteins were analyzed by b 12% SDS-PAGE and c Western blot
analysis with an anti-histidine antibody
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Tat-HSP22 protein transduced into HT-22 cells concentra-
tion- and time-dependently, whereas the control HSP22
protein was not detected in the cells (Fig. 2a and b).
To evaluate how long transduced Tat-HSP22 protein
is stable in HT-22, HT-22 was exposed to Tat-HSP22
protein for 2 h and the cells were cultured for various
times to assess the stability of Tat-HSP22 protein. Tat-
HSP22 protein stability was determined by Western blot
analysis using an anti-histidine antibody. Significant
levels of transduced Tat-HSP22 proteins persisted for
36 h in HT-22 cells (Fig. 2c). We also examined trans-
duced Tat-HSP22 distribution using fluorescence micros-
copy analysis. As shown in Fig. 3a, the green fluorescence
signals were not evident in the control HSP22 protein
treated cells. However, more green fluorescence signals
were evident in the cytosol and nucleus of cells treated
with Tat-HSP22 protein than was evident in the control
HSP22 protein treated cells, indicating that Tat-HSP22
protein transduce into HT-22.
Tat-HSP22 protein inhibits against H2O2-induced HT-22
cell death
To investigate the effects of Tat-HSP22 protein against
HT-22 cell death, a WST-1 assay was performed. HT-22
cells were treated with different doses of Tat-HSP22 pro-
tein (1–5 μM) for 2 h in the presence or absence of
H2O2 (1 mM) for 12 h. The cell viability of HT-22 cells
is shown in Fig. 3b. Our results showed that transduced
Fig. 2 Transduction efficiency of Tat-HSP22 protein into HT-22 cells. a Tat-HSP22 and control HSP22 proteins (0.5–5 μM) were added to the
culture media for 2 h, b Tat-HSP22 and control HSP22 proteins (5 μM) were added to the culture media for 10–120 min and analyzed by
Western blot and the band intensities were measured by densitometer. c Intracellular stability of Tat-HSP22 protein. The cells pretreated with 5 μM
Tat-HSP22 protein were incubated for 1–48 h and analyzed by Western blot and the band intensities were measured by densitometer
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Tat-HSP22 protein markedly increased cell viability from
53 to 79% in the H2O2 treated cells. In contrast, control
HSP22 protein showed no protective effect against H2O2
induced cell death.
Further, we examined the effects of Tat-HSP22 protein
on the production of the intracellular ROS and levels of
DNA damage in H2O2 exposed HT-22 cells by fluores-
cence staining. The cells were pretreated with Tat-HSP22
protein (5 μM) for 2 h and the cells were exposed to
1 mM H2O2 for 2 h. Then, the intracellular ROS and
DNA damage were determined by DCF-DA and TUNEL
staining (Fig. 4). We clearly observed that H2O2 exposure
leads to markedly increased production of intracellular
ROS and DNA damage, while cells pretreated with Tat-
HSP22 protein showed drastically reduced intracellular
ROS and DNA damage levels compared with H2O2
Fig. 3 Transduced Tat-HSP22 protein inhibits H2O2-induced HT-22 cell death. a Cellular distribution of transduced Tat-HSP22 protein was analyzed
using confocal microscopy. HT-22 cells were pretreated with 5 μM of Tat-HSP22 or control HSP22 protein for 2 h and the cells were examined by
Histidine and DAPI staining. Scale bar = 20 μm. b The cells were pretreated with Tat-HSP22 or control HSP22 protein (5 μM) for 2 h and the cells
were incubated in the absence or presence of H2O2 (1 mM) for 12 h. Cell viability was determined using WST-1 assay.
**P < 0.01 compared with
H2O2-treated cells
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exposed HT-22 cells. In contrast, the results of control
HSP22 protein showed no inhibitory effect compared with
H2O2 exposed HT-22 cells, suggesting the effects of Tat-
HSP22 against oxidative stress were caused by inhibiting
H2O2-induced intracellular toxicities.
Tat-HSP22 protein inhibits against H2O2-induced
mitochondrial dysfunction and apoptosis
To elucidate the effects of Tat-HSP22 protein on
mitochondrial dysfunction, we assessed changes in the
mitochondrial membrane potential using JC-1 staining
(Fig. 5a). The results showed that when HT-22 cells
were exposed to H2O2, mitochondrial membrane
potential was significantly increased compared to the
normal control or control HSP22 protein treated cells.
However, the increased levels of mitochondrial mem-
brane potential in the H2O2 exposed cells were sig-
nificantly inhibited by Tat-HSP22 protein.
Next, we determined the inhibitory effects of Tat-
HSP22 protein on the suppression of H2O2-induced
apoptosis. First, we determined the effect of Tat-
HSP22 on transduction into mitochondria of HT-22
Fig. 4 The effect of Tat-HSP22 protein against H2O2-induced intracellular toxicities in HT-22 cells. HT-22 cells were pretreated with 5 μM of
Tat-HSP22 or control HSP22 protein for 2 h and the cells were incubated in the absence or presence of H2O2 (1 mM) for 10 min and 6 h,
respectively. Then, a H2O2-induced oxidative stress levels were measured using DCF-DA staining and the fluorescence intensity was measured
using an ELISA plate reader. b DNA fragmentation was detected by TUNEL staining and quantitative evaluation of TUNEL positive cells confirmed
by cell counting under a phase-contrast microscopy. Scale bar = 50 μm. **P < 0.01 compared with H2O2-treated cells
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cells and changes of cytochrome c expression levels
in separated cytosol and mitochondria fractions
(Fig. 5b). We observed that Tat-HSP22 protein in-
creased mitochondria fraction compared to the con-
trol cells. In addition, Tat-HSP22 protein markedly
inhibited cytochrome c levels in the mitochondria
fraction induced by H2O2. In comparison, control
HSP22 protein did not change the cytochrome c levels.
The results indicate that transduced Tat-HSP22 protein
significantly inhibited cytochrome c release from mito-
chondria to cytosol induced by oxidative stress, sug-
gesting Tat-HSP22 protein suppresses apoptosis induced
by oxidative stress.
Since apoptosis related proteins (Bax, Bcl-2, caspase-3,
and cleaved caspase-3) levels were known to change
during apoptosis, we determined the expression levels of
these proteins (Fig. 6). Tat-HSP22 protein markedly
reduced the expression of Bax and cleaved caspase-3
levels compared to the cells exposed to H2O2 alone, while
Bcl-2 and caspase-3 expression levels were significantly
increased compared to the H2O2 exposed cells. However,
these protein levels were did not change in control HSP22
protein treated cells under the same experimental condi-
tion. These results suggest that the Tat-HSP22 protein
protects against oxidative stress-induced apoptosis by
regulation of apoptosis related protein expression levels.
Fig. 5 Tat-HSP22 protein protects against changes to H2O2-induced mitochondrial membrane potential and cytochrome c release. HT-22 cells
were pretreated with 5 μM of Tat-HSP22 or control HSP22 protein for 2 h and exposed to H2O2 (1 mM) for 20 min and 4 h, respectively.
a Changes of mitochondrial membrane potential were measured using JC-1 assay kit. Scale bar = 50 μm. b After mitochondria and cytosol
fraction were separated using mitochondria isolation kit, transduced Tat-HSP22 protein and cytochrome c levels were determined using Western
blotting in each fraction and band intensity by densitometer. **P < 0.01 compared with H2O2-treated cells
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Neuroprotective effects of Tat-HSP22 protein in CA1
region after ischemic damage
We determined the effects of transduced Tat-HSP22
protein on animal brain tissue and its ability to cross
the BBB. Because the BBB prevents the delivery of
therapeutic agents into the brain, crossing the BBB
is a key point to protect ischemic injury. To confirm
that Tat-HSP22 proteins transduce into the hippo-
campal CA1 region and protect against ischemic injury,
we performed Histidine and NeuN immunostaining.
As shown in Fig. 7a, Tat-HSP22 protein transduced
into the hippocampal CA1 region of animal brain
and markedly protected neurons damage induced by
ischemic injury.
We also determined whether cleaved caspase-3 expres-
sion was involved in ischemic injury. To confirm the pro-
tective effect of Tat-HSP22 protein against ischemic injury
derived cleaved caspase-3 expression, cleaved caspase-3
and NeuN immunostaining were performed 12 h after
ischemia-reperfusion (Fig. 7b). Immunostaining showed
that control HSP22 protein did not protect against ische-
mic injury. Tat-HSP22 protein significantly prevents the
cleaved caspase-3 expression levels induced by ischemic
injury, indicating that Tat-HSP22 protein has the ability to
transduce into animal brain and protect neurons in the
face of ischemic injury.
Further, we examined the protective effects of Tat-
HSP22 protein against ischemic injury (Fig. 8). Cresyl
violet (CV) immunohistochemistry showed that Tat-
HSP22 protein markedly increased neuronal cell viability
in ischemic injury compared to the vehicle group. In
addition, we confirmed neuronal degeneration in the
CA1 region using Fluoro-Jade B (F-JB) staining since
neuronal degeneration causes neuronal cell death. Tat-
HSP22 protein markedly protects against neuronal
degeneration induced by ischemic injury. In contrast,
control HSP22 protein showed the similar results as
the vehicle group. Our results demonstrate that
Tat-HSP22 protein efficiently promotes neuronal cell
survival induced in ischemic injury.
Fig. 6 Effect of Tat-HSP22 protein against H2O2-induced Bax, Bcl-2, and caspase-3 expression levels in HT-22 cells. The cells were pretreated with
5 μM of Tat-HSP22 or control HSP22 protein for 2 h and exposed to H2O2 (1 mM) for 4 h and 6 h, respectively. Then, the levels of Bax, Bcl-2,
caspase-3 and cleaved caspase-3 were measured by Western blotting and band intensity by densitometer. **P < 0.01 compared
with H2O2-treated cells
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Since the activation of astrocytes and microglia are
known to be strongly involved in ischemic injury, we
further performed GFAP and Iba-1 staining to detect
whether Tat-HSP22 protein prevents astrocytes and
microglia activation induced by ischemic injury. GFAP
and Iba-1 staining showed that control HSP22 protein
demonstrated a similar pattern as the vehicle group,
while Tat-HSP22 protein drastically protected against as-
trocytes and microglia activation induced by ischemic
injury. As shown in Fig. 8, our results indicate that Tat-
HSP22 protein significantly prevented the neuronal
cell death in the CA1 region induced by ischemic
injury.
Discussion
Heat shock protein 22 (HSP22) known as H11 kinase,
E21G1, and HSPB8 is a member of the small HSP family
of proteins containing a α-crystalline domain and has
been demonstrated to have protective effect against
various conditions including oxidative stress, aging, can-
cer, and apoptosis [8–13]. Although HSP22 protein is
well known to function in the pathophysiological pro-
cesses of various cancer cells, the exact function and
mechanism of HSP22 protein in hippocampal neuronal
cell damage from oxidative stress and in an ischemic
brain injury animal model remains to be clarified. There-
fore, we investigated the effects of HSP22 protein against
Fig. 7 Transduction of Tat-HSP22 protein into gerbil brain and its protective effects. Gerbils were treated with single injections of Tat-HSP22
(2 mg/kg) or control HSP22 protein and killed. a 7 days after ischemic insults, transduced Tat-HSP22 protein was confirmed using an anti-Histidine,
NeuN, DAPI, and Alexa immunostaining. Scale bar = 50 μm. b The changes of cleaved caspase-3 expression levels were confirmed using
an anti-cleaved caspase-3 staining after 12 h ischemic insults. Scale bar = 18.8 μm. **P < 0.01, significantly different from the vehicle group
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oxidative stress-induced neuronal cell damage to clarify
the function and mechanism used Tat-HSP22 protein,
which is known for the ability to be efficiently delivered
into cells or tissues. Since HIV-1 Tat protein transduction
domain (PTD) fusion protein has the ability to efficiently
transduce into cells by crossing the plasma membrane or
brain tissue therefore crossing the blood-brain barrier
(BBB), numerous studies have demonstrated the potential
of its therapeutic protein application in cells or tissues
against various diseases [11, 17–26].
In this study, we constructed the recombinant Tat-
HSP22 protein expression vector and purified Tat-
HSP22 protein with Ni-NTA affinity chromatography.
Purified Tat-HSP22 protein was evaluated by SDS-PAGE
and Western blot analysis. We subsequently confirmed
the transduction ability of Tat-HSP22 protein into HT-
22 cells. Our data showed that Tat-HSP22 protein trans-
duced into HT-22 cells dose- and time-dependently. In
addition, we confirmed the distribution of transduced
Tat-HSP22 protein in HT-22 cells by immunofluores-
cence staining. Transduced Tat-HSP22 protein distrib-
uted in the cytosol and nuclei of HT-22 cells. These
results indicate that we successfully constructed Tat-
HSP22 protein expression vector and purified Tat-
HSP22 protein efficiently transduced into HT-22 cells.
Consistent with other studies, which have demonstrated
that various purified PTD fusion proteins efficiently
transduce into cells [19–25, 27, 28].
Hydrogen peroxide (H2O2), a mild oxidant, is a known
by-product of a normal biological processes in cells.
However, high levels of H2O2 are very toxic and critical
for cell survival and signaling pathways because reactive
oxygen species (ROS) including superoxide anion and
hydroxyl radical are produced in the presence of high
levels of H2O2 [29–31]. Also, generated ROS is well
known to contribute to cellular damage by destroying
macromolecules including proteins, lipids, and nucleo-
tides [32]. Thus, we examined the effect of Tat-HSP22
protein against H2O2-induced cellular toxicities. We
demonstrated that transduced Tat-HSP22 protein signifi-
cantly increased cell survival compared to the cells
treated only with H2O2-treated. Also, Tat-HSP22 protein
markedly inhibited H2O2-induced intracellular oxidative
stress and DNA fragmentation levels compared to the
H2O2-treated cells. Other studies have shown that over-
expression of HSP22 promotes cardiac cell survival and
HSP22 has protective effects in the stress condition of
cardiac cells via regulating the PI3K/Akt pathways [33].
Also, overexpression of HSP22 increased resistance to
oxidative stress and longevity in flies whereas the ab-
sence of HSP22 expression decreased the lifespan and
resistance to stress, suggesting that HSP22 overexpres-
sion play beneficial roles during aging [34, 35]. In agree-
ment with these results, we have shown that transduced
Tat-HSP22 protein prevents HT-22 cell death caused by
H2O2-induced oxidative stress.
Several studies have demonstrated that mitochondria
is the main generator of ROS and excessive ROS eventu-
ally leads to mitochondria dysfunction and cell death by
induction of apoptosis in various conditions including
aging and ischemic injury [36–38]. Further, apoptosis is
known to play a critical role in the survival of cells in
various conditions including ischemia. The balance of
pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) proteins
Fig. 8 Neuroprotective effects of Tat-HSP22 protein against ischemic damage. Gerbils were treated with single injections Tat-HSP22 (2 mg/kg) or
control HSP22 protein and killed after 7 days. Neuronal cell viability after ischemic insults were determined using Cresyl violet, GFAP, Iba-1, and
F-JB immunostaining. Relative numeric analysis of CV, GFAP, Iba-1, and F-JB positive neurons in the CA1 region. Scale bar = 400 and 50 μm.
**P < 0.01, significantly different from the vehicle group
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is important to cell survival. Activation of Bax induced
cell death by cytochrome c release from the mitochon-
dria and activation of caspase-3 [39, 40]. Thus, we deter-
mined the effect of transduced Tat-HSP22 protein on
H2O2-induced mitochondria apoptotic signal pathway.
Tat-HSP22 protein significantly prevented mitochondrial
dysfunction and inhibited the release of cytochrome c
from mitochondria to cytosol as well as inhibited cell
death via regulation of the expression of the apoptotic
proteins Bax, Bcl-2, and active caspase-3. Corroborating
our results, other studies have demonstrated that over-
expression of HSP22 protein increase resistance to oxi-
dative stress and prevents mitochondrial dysfunction by
reducing ROS production during the aging process of
flies [14]. Also, overexpression of HSP22 protein inhibits
the mitochondria dependent apoptosis through regula-
tion of pro-apoptotic and anti-apoptotic proteins expres-
sion in myocardial infarction [41].
Since it is difficult to cross the BBB it is difficult to
deliver therapeutic drugs or agents into brain, the thera-
peutic effects of drugs or agents is limited in neuronal
diseases including ischemia. However, PTD fusion pro-
teins are known to be able to delivery therapeutic
proteins into the brain which is considered a powerful
tool in the development of therapeutic drugs or agents
in neuronal diseases [17–19, 42]. In a previous study, we
demonstrated that Tat fused protein inhibited neuronal
cell death in ischemic injury via crossing the BBB [22].
In this study, we determined the effect of Tat-HSP22
protein against ischemia in an animal model. Our results
showed that Tat-HSP22 protein efficiently transduced
into the hippocampal CA1 region where it markedly
inhibited neuronal cell death. Tat-HSP22 protein also
decreased active caspase-3 expression levels in the
hippocampal CA1 region. Several studies have shown
that HSP22 protein expression is increased in a swine
ischemia model and in ischemia patients, suggesting
that HSP22 protein plays protective roles in ischemic
injury [43, 44]. In addition, HSP22 protein enhances
cardiac cell survival by prevention of myocardial in-
farction in ischemic preconditioning [41]. Other stud-
ies have also shown that increased HSP22 mRNA is
associated with the improvement in renal function
after ischemia [45].
Several studies have demonstrated that the activation
of microglia and astrocytes as well as the expression of
abundant glial fibrillary acidic protein are highly associ-
ated with neuronal diseases including ischemic injury
[46–49]. Using GFAP, Iba-1, and F-JB immunohisto-
chemistry, we demonstrated that Tat-HSP22 protein
markedly reduced activation of microglia and astrocytes
as well as the expression of glial fibrillary acidic protein
in the hippocampal CA1 region. These results indicate
that Tat-HSP22 protein plays an important role in
preventing neuronal damage via regulation of gliosis and
neuronal degeneration resulting from ischemia. How-
ever, further studies are required to understand the exact
mechanisms in ischemic injury.
In conclusion, we showed that Tat-HSP22 protein
transduced into hippocampal HT-22 cells in vitro and
the CA1 region in vivo and significantly inhibited neur-
onal cell death caused by oxidative stress, suggesting
that Tat-HSP22 protein provides a potential therapeutic
strategy to prevent oxidative stress-induced diseases
including ischemic injury.
Methods
Cell culture and cell viability assay
Hippocampal neuronal cells (HT-22) were cultured as
described previously [27]. To assess cell viability, HT-
22 cells were preincubated with Tat-HSP22 or control
HSP22 (1–5 μM) for 2 h before treatment with
hydrogen peroxide (1 mM) for 12 h. Cell viability was
determined by a WST-1 kit (Daeillab Service, Seoul,
Korea) [27].
Construction, purification, and transduction of
recombinant Tat-HSP22 into HT-22
The HSP22 full length cDNA amplification was performed
using human HSP22 specific primers as follows; the pri-
mer of forward as 5′-CTCGAGATGGCTGACGGTCAG-
3′ and the primer of reverse as 5′-GGATCCTCAGGTAC
AGGTGACTTCCT-3′. Subsequently, we constructed cell
permeable Tat-HSP22 and control HSP22 expression
vector as previously described [22].
After transformation of constructed Tat-HSP22 and
control HSP22 protein expression vector into Escheri-
chia coli BL21 (DE3), these plasmids were cultured in
LB medium at 37 °C for 4 h including ampicillin (50 μg/
ml) and IPTG (0.5 mM) to purify Tat-HSP22 and con-
trol HSP22 protein. Then, overexpressed Tat-HSP22 and
control HSP22 proteins were harvested by centrifugation
and the proteins were purified using affinity chromato-
graph as described in a previous study [22]. Purified Tat-
HSP22 protein concentration was determined using a
Bradford assay [50].
For transduction of Tat-HSP22 into HT-22, the pro-
teins were added to the HT-22 culture medium at
different concentrations (0.5–5 μM) for 2 h or treated
over various times (10–120 min) at the same level
(5 μM). Then, the HT-22 was washed with trypsin-
EDTA and PBS. The levels of transduced Tat-HSP22
was identified by Western blotting and confocal
microscope analysis (FV-300; Olympus, Tokyo, Japan)
[23]. Western blotting was performed as previously
described [23, 51]. The protein bands were analyzed
ECL (Amersham, Franklin Lakes, NJ, USA) using the
indicated specific antibody.
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Fluorescence microscopy analysis
To detect the intracellular distribution of transduced
Tat-HSP22 into HT-22, fluorescence microscopy was
performed as described previously [24]. After exposure
of HT-22 to Tat-HSP22 (5 μM) for 2 h, the cells were
washed twice with PBS. Subsequently, the cells were
staining with Histidine primary Ab and Alexa Fluor
488-conjugated secondary Ab. After washing, the cells
were staining with DAPI (Roche, Mannheim, Germany)
and observed under a FV-300 confocal microscope
(Olympus, Tokyo, Japan).
Measurement of intracellular toxicities
To examine the function of Tat-HSP22 against oxidative
stress-induced HT-22 cell toxicities, HT-22 were treated
with Tat-HSP22 (5 μM) after exposure or non-exposure
to hydrogen peroxide for 2 h. Then, the hydrogen
peroxide-induced cellular toxicities including cellular
ROS (DCF-DA staining), DNA fragmentation (TUNEL
staining), and mitochondria dysfunction levels (JC-1
staining) were measured by fluorescence microscopy
analysis [22–24, 52].
Experimental animals
Male gerbils obtained from the Experimental Animal
Center, at Hallym University were housed at 23 °C, with
humidity of 60%, and exposed to 12 h periods of light
and dark with free access to food and water. All experi-
mental procedures involving animals and their care
conformed to the Guide for the Care and Use of
Laboratory Animals of the National Veterinary Research
& Quarantine Service of Korea and were approved by
the Institutional Animal Care and Use Committee of
Soonchunhyang University [SCH 15-0005].
Effects of Tat-HSP22 on ischemic animal model
To investigate the effects of HSP22 against ischemic
insults, the animals were divided into 4 groups (7 gerbils
in each groups). Group 1, sham operated control group;
group 2, ischemia operated vehicle group; group 3,
control HSP22 protein (2 mg/kg) + ischemia operated
group; group 4, Tat-HSP22 protein (2 mg/kg) + ischemia
operated group. Control HSP22 and Tat-HSP22 pro-
teins were intraperitoneally injected 30 min after
ischemia-reperfusion.
In addition, we examined changes in cleaved caspase-3
expression levels caused by Tat-HSP22 protein in an
ischemic animal model. 30 min after ischemia-reperfusion,
control HSP22 and Tat-HSP22 proteins were intraperitone-
ally injected, the animals were sacrificed after 12 h to
confirm the changes of cleaved caspase-3 expression levels
by immunostaining.
Induction of ischemic injury was performed as previously
described [22, 27]. Briefly, ischemia was induced by
the occlusion of arteries with non-traumatic aneurysm
clips. 7 days after induction of ischemic injury, the
effects of HSP22 proteins were examined by immuno-
histochemistry [22, 27, 28].
Immunostaining and immunohistochemistry analysis
To determine the effects of transduced Tat-HSP22
protein against neuronal cell death and changes of
cleaved-capase-3 expression levels in ischemic animal
model, NeuN, histidine, and cleaved caspase-3 immuno-
staining were performed. Briefly, the sections were
stained with NeuN (diluted 1:1,000; Chemicon Inter-
national, Temecula, CA, USA), histidine (diluted 1:1,000;
Santa Cruz, CA, USA), cleaved caspase-3 (diluted
1:1,000; Cell Signaling Technology, Beverly, MA, USA).
The sections were also incubated in a mixture of FITC-
and Cy3-conjugated secondary antisera (1:200; Amersham,
USA) for 1 h and mounted with DAPI (Vector, Laborator-
ies, CA, USA).
To determine the effect of transduced Tat-HSP22
protein against neuronal cell survival and delayed neur-
onal damage in ischemic animal model, we performed
CV, GFAP, Iba-1, and F-JB immunohistochemistry as
previously described [22, 27, 28].
Cell counting and statistical analysis
For quantification of immunostaining, we performed a
cell count in the hippocampal area as described in a
previous study [22, 27, 28]. All data are presented as the
mean ± SEM. The different between the groups were
analyzed using one-way ANOVA with Bonferroni’s test.
A value of P < 0.05 was considered statistically significant
different.
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